- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07589075
Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation (SGLT-2/PCOS)
Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation in Women With Polycystic Ovarian Syndrome
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The study will be a randomized controlled clinical trial. Once the eligibility from screening visit is determined prior to baseline visit, randomization will be made by computer randomization for women who are admitted to Beni-Suef University Hospital. The Sample size will be 500 divided equally into 4 groups calculated with power=0.8.
Before initiation of the study, the population will be divided randomly into 4 equal groups: group A, B, C and D. The adjuvant therapy of each group will be group (A) Metformin , group (B) Dapagliflozin , Group(C) Combined Dapagliflozin-Metformin and group (D) with no adjuvant therapy (control group). The adjuvant therapy will be taken once daily with a main meal and started one month before initiation of letrozole. All groups will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
Ovulation rate (percentage of ovulatory cycles in the whole follow up period),Pregnancy rate (clinical pregnancy will be considered when an intrauterine gestational sac is seen and presence of a fetal heartbeat),Serum progesterone on day 21,Endometrial thickness at the time of ovulation and Weight, waist/hip ratio, height and body mass index (BMI) will be measured
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Banī Suwayf, Ägypten, 62517
- Gynecology and Reproductive department in Beni-Suef University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
Pre-menopausal women aged 20-40 with primary or secondary infertility and PCOS which render them unable to become pregnant. Diagnosis of PCOS will based on European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) criteria, the diagnosis is made when at least two of the following criteria are met: oilgo and/or anovulation (infrequent or no ovulation), clinical and/or biochemical signs of hyperandrogenism including hirsutism, acne and/or increased testosterone levels or polycystic ovaries on ultrasound (defined as those containing at least 12 follicles measuring 2-9 mm in diameter arranged peripherally around an echo-dense stroma and/or with increased ovarian volume of at least 10 ml).
Exclusion Criteria:
Other causes of hyperandrogenism mimic PCOS such as congenital adrenal hyperplasia, Cushing's syndrome, or androgen secreting tumors are excluded.
Persistent hyperprolactinemia, thyroid dysfunction defined as TSH < 0.2 mIU/ML or >5.5 mIU/mL) or patients with menopausal levels of FSH (> 15 mIU/mL) (A normal level within the last year is adequate for enter the study).
Liver disease is defined as AST or ALT > 2 times normal or total bilirubin >2.5 mg/dL, kidney disease defined as BUN > 30 mg/dL or serum creatinine> 1.4 mg/dL or significant anemia defined as Hemoglobin < 10 mg/dL.
Women with Type I or II diabetes mellitus who are poorly controlled (defined as a HA1c level > 7.0%).
Untreated poorly controlled hypertension is defined as a systolic blood pressure ≥ 160 mm Hg or a diastolic ≥ 100 mm Hg obtained on two measures obtained at least 60 minutes apart.
History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.
Women who have undergone a bariatric surgery procedure in the recent past (<12 months) and are in a period of acute weight loss or have been advised against pregnancy by their bariatric surgeon.
Presence of any urinary symptom such as frequency, urgency, or bloody micturition.
In case of metabolic acidosis, osteoporosis, endometrial hyperplasia, or endometrial neoplasia.
Women who had gonadotropin induction, ovarian drilling before or women with hypergonadotropic hypogonadism or functional ovarian cysts (> 5cm).
Criteria of IVF/ICSI as poor Response, no Eggs or ectopic pregnancy. Women who receive antidiabetic medications such as insulin, thiazolidinediones, acarbose, or sulfonylureas are likely to confound the effects of study medication or who are currently receiving metformin XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically excluded.
Concomitant use of medication that could interfere with the absorption, metabolism, and excretion of drugs involved in the study as the use of Furosemide, cimetidine increase metformin concentration and nifedipine enhances the absorption of metformin.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: "metformin"
will take Metformin 1000mg as adjuvant therapy
|
will take Metformin 1000 mg once daily with a main meal and started one month before initiation of the first cycle of induction.
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
|
|
Experimental: "Dapagliflozin"
will take Dapagliflozin 10mg as adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
will take Dapagliflozin 10mg once daily with a main meal and started one month before initiation of the first cycle of induction.
|
|
Experimental: "Dapagliflozin-Metformin"
will take combined Dapagliflozin-Metformin 5/1000 as adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
will take Combined Dapagliflozin-Metformin 5/1000mg once daily with a main meal and started one month before initiation of the first cycle of induction.
|
|
Sonstiges: "control"
will take letrozole 2.5mg the no adjuvant therapy
|
will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Ovulation rate
Zeitfenster: "through study completion, an average of 1 year".
|
percentage of ovulatory cycles
|
"through study completion, an average of 1 year".
|
|
Pregnancy rate
Zeitfenster: "through study completion, an average of 1 year".
|
when an intrauterine gestational sac is seen and presence of a fetal heartbeat)
|
"through study completion, an average of 1 year".
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Serum progesterone
Zeitfenster: "through study completion, an average of 1 year".
|
Serum progesterone
|
"through study completion, an average of 1 year".
|
|
Endometrial thickness
Zeitfenster: "through study completion, an average of 1 year".
|
Endometrial thickness
|
"through study completion, an average of 1 year".
|
|
Weight
Zeitfenster: "through study completion, an average of 1 year".
|
Weight in kilogram
|
"through study completion, an average of 1 year".
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IORG2226240
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Induktion des Eisprungs
-
Kocaeli UniversityAbgeschlossenRapid Sequence Induction IntubationTruthahn
-
SPD Development Company LimitedAbgeschlossen
-
SPD Development Company LimitedAbgeschlossenOvulationVereinigtes Königreich
-
SPD Development Company LimitedAbgeschlossen
-
Wyeth is now a wholly owned subsidiary of PfizerAbgeschlossen
-
University of Southern CaliforniaSociety of Family PlanningAbgeschlossenEmpfängnisverhütung | OvulationVereinigte Staaten
-
Ouraring Inc.UCSF Center for Reproductive HealthAbgeschlossenMenstruation | Menstruationszyklus | OvulationVereinigte Staaten
-
Ain Shams UniversityAbgeschlossenRapid Sequence Induction und IntubationÄgypten
-
University of MalayaUnbekanntEndotracheale Intubation in Kopfhochlagerung im Bett bei Rapid Sequence InductionMalaysia
Klinische Studien zur Metformin 1000 mg
-
Dong Wha Pharmaceutical Co. Ltd.Abgeschlossen
-
Disphar International B.V.ZurückgezogenVergleichende BioverfügbarkeitJordanien
-
Handok Inc.AbgeschlossenGesunde FreiwilligeKorea, Republik von
-
SandozAbgeschlossen
-
Humanis Saglık Anonim SirketiAbgeschlossenTyp 2 DiabetesJordanien
-
GlaxoSmithKlineAbgeschlossenDiabetes mellitus, Typ 2Vereinigte Staaten, Taiwan, Argentinien, Kanada, Philippinen, Korea, Republik von, Mexiko, Brasilien, Pakistan
-
Chong Kun Dang PharmaceuticalAbgeschlossenDiabetes mellitus, Typ IIKorea, Republik von
-
Badr UniversityNoch keine RekrutierungRückenmarksverletzung (SCI)Ägypten
-
Dong-A ST Co., Ltd.AbgeschlossenTyp 2 Diabetes mellitusKorea, Republik von